US5124314A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical compositions containing amylin
Assignee: Amylin Pharmaceuticals LLC
•
Filing: 1991-06-10
•
Granted: 1992-06-23
•
Expires: 2011-06-10
Abstract
Abstract The present invention relates to pharmaceutical compositions for use in treating diabetes Mellitus or hypoglycemia containing Amylin as the effective additive.
Inventors
- 👤 Garth J. S. Cooper
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 20:07
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/225; A61K33/00; A61K33/24; A61K33/30; A61K38/28; A61P; A61P3/00; A61P3/08; A61P3/10; A61P5/00; A61P5/48; C; C07; C07K; C07K14/00; C07K14/435; C07K14/575
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
28 words
A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises a therapeutically effective amount of amylin in association with a pharmaceutically acceptable carrier.
Claim 2
Dependent Claim
28 words
A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises a therapeutically effective amount of amylin in association with a pharmaceutically acceptable carrier.
Claim 3
Dependent Claim
35 words
A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises therapeutically effective amount of amylin and a therapeutically effective amount of an insulin in association with a pharmaceutically acceptable carrier.
Claim 4
Dependent Claim
35 words
A pharmaceutical composition for use in the treatment of diabetes mellitus or hypoglycemia which comprises therapeutically effective amount of amylin and a therapeutically effective amount of an insulin in association with a pharmaceutically acceptable carrier.
Claim 5
Dependent Claim
11 words
The pharmaceutical composition of claim 1 wherein said composition is lyophilized.
Claim 6
Dependent Claim
11 words
The pharmaceutical composition of claim 2 wherein said composition is lyophilized.
Claim 7
Dependent Claim
18 words
The pharmaceutical composition of claim 1 wherein said composition is disposed in a vehicle suitable for delayed-release administration.
Claim 8
Dependent Claim
18 words
The pharmaceutical composition of claim 2 wherein said composition is disposed in a vehicle suitable for delayed-release administration.
Claim 9
Dependent Claim
34 words
The pharmaceutical composition of claim 1 which comprises a suspension of said amylin, said suspension being formulated with a zinc salt in a pharmaceutically acceptable buffer, and said suspension being suitable for parenteral administration.
Claim 10
Dependent Claim
37 words
The pharmaceutical composition of claim 2 which comprises a suspension of said amylin and said insulin, said suspension being formulated with a zinc salt in a pharmaceutically acceptable buffer, and said suspension being suitable for parenteral administration.
Claim 11
Dependent Claim
16 words
The pharmaceutical composition of any of claims 1-7 or 8 wherein said amylin is human amylin.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-06-23 | 1995-12-23 | 1996-06-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-06-23 | 1999-12-23 | 2000-06-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-06-23 | 2003-12-23 | 2004-06-23 | $7700.00 | Window Closed / Lapsed |